Company
Our Story
Aerys Biosciences, a clinical-stage biopharmaceutical company based in Palo Alto, California, was founded as a spin-out from Stanford University and Greenstone Biosciences. Our origins lie in breakthrough discoveries published in Cell and other leading scientific journals, forming the foundation for a new generation of therapies targeting fibro-inflammatory lung diseases such as idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
Rooted in Stanford’s translational research ecosystem and Silicon Valley’s culture of innovation, Aerys integrates cutting-edge science with clinical insight to accelerate the path from discovery to patient care. Guided by a network of renowned physicians and scientists, we are dedicated to advancing precision small-molecule therapies that redefine the standard of treatment for fibrotic and vascular diseases.
Our Approach
At Aerys Biosciences, we leverage next-generation discovery and development platforms to design small-molecule therapies with disease-modifying potential for pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Our programs are built on human induced pluripotent stem cell (hIPSC)–based models that recapitulate the physiological signaling mechanisms of human biology, providing highly predictive and translationally relevant insights. In close collaboration with Stanford University and leading investigators, we are advancing innovative repurposing strategies and FDA-approved early-stage clinical trials to translate these discoveries into meaningful patient outcomes. By integrating human-relevant science with rigorous clinical execution, Aerys is redefining how fibro-inflammatory lung diseases are understood and treated—as we move towards pioneering first-in-human therapies to deliver more effective treatments for the future.